Dupixent drives a larger share of Sanofi's revenue, with atopic dermatitis, asthma, and CRSwNP as core indications. Learn ...
BROADEN2 Phase 2b trial in atopic dermatitis (AD) ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma ongoing, with data expected in late-2027 Initiated dosing in KT-579 ...
I had breast cancer in my left breast 14 years ago. I was treated with chemotherapy and radiation after a lumpectomy and the removal of 14 lymph ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results